Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Class III antiarrhythmic agents: the next wave

J L Bauman1

  • 1University of Illinois at Chicago, Department of Pharmacy Practice, USA.

Pharmacotherapy
|March 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of the cost of prescription drugs on clinical outcomes in indigent patients with heart disease.

Pharmacotherapy·2002
Same author

Analysis of the use of digoxin immune fab for the treatment of non-life-threatening digoxin toxicity.

Journal of cardiovascular pharmacology and therapeutics·2001
Same author

Amiodarone: the re-emergence of a unique antiarrhythmic drug. Introduction.

Pharmacotherapy·1998
Same author

Rationale, development, and clinical outcomes of a multidisciplinary amiodarone clinic.

Pharmacotherapy·1998
Same author

Pharmacists and infectious diseases specialists.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·1998
Same author

Prolongation of the QT interval related to cisapride-diltiazem interaction.

Pharmacotherapy·1998
Same journal

Comment on "Pharmacokinetic Analysis of Intravenous Push Cefepime in Critically Ill Patients With Sepsis".

Pharmacotherapy·2026
Same journal

Response to Comment on "Pharmacokinetic Analysis of Intravenous Push Cefepime in Critically Ill Patients With Sepsis".

Pharmacotherapy·2026
Same journal

The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers.

Pharmacotherapy·2026
Same journal

Menopausal Hormone Therapy: A Narrative Review of Contemporary Evidence.

Pharmacotherapy·2026
Same journal

Getting It Right the Second Time: How Can we Optimize First-Generation Cephalosporin Dosing for Skin and Soft Tissue Infections in the 21st Century?

Pharmacotherapy·2026
Same journal

Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case-Control Study.

Pharmacotherapy·2026
See all related articles

Class III antiarrhythmic drugs like sotalol hydrochloride and amiodarone hydrochloride effectively treat ventricular arrhythmias. While both prolong action potential, they differ in side effects and proarrhythmic potential, requiring careful patient selection.

Area of Science:

  • Pharmacology
  • Cardiology
  • Electrophysiology

Background:

  • Class III antiarrhythmic agents, including sotalol hydrochloride and amiodarone hydrochloride, are increasingly utilized for ventricular arrhythmia management.
  • These drugs prolong cardiac action potential and increase refractoriness, crucial mechanisms in arrhythmia control.
  • Amiodarone has demonstrated potential mortality benefits in specific patient groups compared to Class I agents.

Purpose of the Study:

  • To differentiate the distinct pharmacologic profiles of sotalol hydrochloride and amiodarone hydrochloride.
  • To compare the side effect profiles and proarrhythmic actions of these two key Class III antiarrhythmics.
  • To highlight the importance of distinguishing these agents from pure potassium channel blockers.

Main Methods:

Related Experiment Videos

  • Comparative analysis of the pharmacological properties of sotalol hydrochloride and amiodarone hydrochloride.
  • Review of clinical data regarding efficacy, side effects, and proarrhythmic potential.
  • Examination of specific adverse event profiles, including beta-adrenergic blockade effects for sotalol and pulmonary toxicity for amiodarone.

Main Results:

  • Sotalol hydrochloride is associated with beta-adrenergic blockade side effects and a proarrhythmic incidence similar to Class Ia agents.
  • Amiodarone hydrochloride carries risks of pulmonary toxicity and other adverse events but rarely causes torsades de pointes.
  • Pure Class III potassium channel blockers, exemplified by dextro-sotalol, show increased mortality in post-MI patients with reduced ventricular function or heart failure.

Conclusions:

  • Sotalol hydrochloride and amiodarone hydrochloride possess unique pharmacological characteristics, necessitating careful consideration of their individual risk-benefit profiles.
  • Understanding the specific side effects and proarrhythmic tendencies is crucial for safe and effective clinical application.
  • Clinical differentiation from pure potassium channel blockers is vital, particularly in high-risk cardiac populations.